UK markets close in 8 hours 15 minutes

Sanofi (SNYNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
89.51+5.05 (+5.98%)
At close: 03:03PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close84.46
Bid0.00 x 0
Ask0.00 x 0
Day's range88.50 - 89.51
52-week range83.55 - 114.80
Avg. volume54,269
Market cap116.167B
Beta (5Y monthly)0.36
PE ratio (TTM)16.48
EPS (TTM)5.43
Earnings dateN/A
Forward dividend & yield3.52 (4.17%)
Ex-dividend date06 May 2022
1y target estN/A
  • Globe Newswire

    Press Release: Sanofi provides update on amcenestrant clinical development program

    Sanofi provides update on amcenestrant clinical development program PARIS, August 17, 2022. Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD). The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial evaluating amcenestrant in combination with palbociclib compared with letrozole in combination with palbociclib in patients with estrogen receptor-positive

  • Yahoo Finance Video

    Pharma companies see sales slump amid ongoing Zantac litigation

    Yahoo Finance health care reporter Anjalee Khemlani looks at which pharmaceutical stocks are being affected by litigation surrounding alleged carcinogenic materials in Zantac derivatives.

  • Zacks

    PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation

    Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).